PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis
Doing an MRI first and biopsying only suspicious areas found more clinically significant prostate cancers and fewer harmless ones than standard biopsy, while sparing a quarter of men any biopsy at all.
Overview
Multicentre randomised non-inferiority trial of 500 biopsy-naive men with suspected prostate cancer randomised to MRI with targeted biopsy of suspicious lesions only (no biopsy if MRI was negative) or standard transrectal ultrasound-guided 10 to 12 core biopsy.
Clinically significant cancer was detected in 38 percent of the MRI group against 26 percent with standard biopsy, clinically insignificant cancer in 9 versus 22 percent, and 28 percent of MRI-group men avoided biopsy.
- Clinically significant cancer detected in 38 percent vs 26 percent.
- Clinically insignificant cancer in 9 percent vs 22 percent; 28 percent of MRI arm avoided biopsy.
Pre-biopsy MRI with targeted sampling is now the standard diagnostic pathway for suspected prostate cancer, reducing overdiagnosis of low-risk disease.
- Targeted biopsy alone may miss some significant cancers; many centres combine targeted and systematic cores.
- Depends on MRI quality and reader expertise.
Similar pages
not linked directly; found by shared links- Key paperProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer
Shares Localised prostate cancer, very low and low risk, New England Journal of Medicine.
- Key paperProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer
Shares Localised prostate cancer, very low and low risk, New England Journal of Medicine.
- TechnologyMultiparametric prostate MRI (PI-RADS)
Shares PRECISION, Localised prostate cancer, very low and low risk.